T-Prime base w/enclomiphene

Route: Oral capsule.

• Take by mouth once daily as directed by the prescriber.
• May be taken with or without food; consistent timing each day is recommended.
• Swallow capsule whole; do not crush or open.
• The "T-Prime" base is an excipient formulation designed to support absorption; follow prescriber instructions for the specific preparation dispensed.

Dosing is individualized by the prescriber based on baseline testosterone, LH, FSH, and clinical presentation. Common reference ranges from published literature include:

• Typical starting dose: 12.5 mg orally once daily.
• Titration: May increase to 25 mg once daily based on 4-to-6-week laboratory response (total testosterone, LH, FSH).
• Monitor testosterone levels 4–6 weeks after initiation or dose change; target serum testosterone 400–700 ng/dL (prescriber-determined).
• Dosing decisions rest with the prescribing clinician.

• Enclomiphene (SERM): Competitively antagonizes estrogen receptors (ERα) in the hypothalamus and anterior pituitary. In males, circulating estradiol (converted peripherally from testosterone via aromatase) exerts negative feedback on GnRH pulsatility and LH/FSH secretion. Enclomiphene blocks this feedback loop, increasing GnRH pulse frequency → elevated LH secretion from the pituitary → Leydig cell stimulation → endogenous testosterone production. FSH co-stimulation supports Sertoli cell function and maintains spermatogenesis. Because enclomiphene acts upstream (central) rather than replacing testosterone directly, HPG axis integrity and fertility are preserved—a key distinction from testosterone replacement therapy (TRT).

Indication context: Enclomiphene is used in men with secondary hypogonadism (low testosterone with normal or low-normal LH/FSH), particularly in reproductive-age men who wish to maintain or restore fertility while raising endogenous testosterone levels. It is not indicated in primary hypogonadism (testicular failure), where LH/FSH are already elevated. Published trials have demonstrated significant increases in total testosterone and LH with preserved or improved sperm parameters.

Monitoring:

• Baseline: total testosterone (AM fasting), free testosterone, LH, FSH, estradiol, CBC, CMP.
• Follow-up labs at 4–6 weeks post-initiation; repeat every 3–6 months once stable.
• Semen analysis at 3 months if fertility preservation is a treatment goal.
• Monitor estradiol—compensatory aromatization may elevate estradiol as testosterone rises; aromatase inhibitor may be added if symptomatic.
• Polycythemia: monitor hematocrit; less risk than TRT but possible.
• Visual disturbances: rare but reported with clomiphene-class SERMs; discontinue and evaluate if visual symptoms occur.

Contraindications:

• Primary hypogonadism (hypergonadotropic hypogonadism): enclomiphene cannot overcome testicular failure.
• Known hypersensitivity to clomiphene or enclomiphene.
• Liver disease or hepatic impairment: SERMs are hepatically metabolized.
• Uncontrolled thyroid or adrenal dysfunction (evaluate and treat before initiating).

Warnings & Precautions:

• Visual disturbances (blurred vision, scotomata, photopsia): rare class effect of clomiphene-type SERMs; discontinue immediately if visual symptoms occur and obtain ophthalmologic evaluation.
• Estradiol elevation: rising testosterone will increase peripheral aromatization; monitor estradiol and manage if symptomatic (gynecomastia, water retention, mood changes).
• Polycythemia: elevated testosterone may increase erythropoiesis; monitor hematocrit.
• Not for use in female patients (distinct from clomiphene's use in ovulation induction).
• Prostate safety: monitor PSA annually in patients >40 years; enclomiphene raises testosterone but prostate safety data are limited compared to TRT.

Drug Interactions:

• Aromatase inhibitors: may be co-prescribed to manage estradiol rise; monitor closely to avoid estrogen deficiency symptoms.
• Testosterone therapy: concurrent use defeats the purpose (suppresses HPG axis); avoid combining.

Common Side Effects: Acne, libido changes, mood variability; elevated estradiol causing gynecomastia or fluid retention; headache; rarely, visual disturbances.

Store at room temperature (15–25°C). Protect from moisture and light. Keep in original sealed container. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding per USP <795> guidelines. Keep out of reach of children.

How is enclomiphene different from testosterone replacement therapy (TRT)?

TRT provides exogenous testosterone directly, which suppresses the HPG axis, reduces LH/FSH, shrinks testicular volume, and impairs or halts sperm production. Enclomiphene works upstream—it blocks estrogen's suppression of the pituitary, causing the body to produce its own testosterone. This preserves testicular function and fertility, which is critical for men who may wish to conceive.

How is enclomiphene different from clomiphene (Clomid)?

Clomiphene citrate is a mixture of two isomers: enclomiphene (trans, estrogenic antagonist at pituitary) and zuclomiphene (cis, partial agonist). Zuclomiphene accumulates with repeated dosing and can have estrogenic effects. Enclomiphene is the purified trans-isomer with a cleaner antagonist profile and faster clearance, which may reduce estrogenic side effects.

How long before testosterone levels improve?

Most patients see an increase in LH and testosterone within 2–4 weeks. Labs are typically rechecked at 4–6 weeks. Full optimization may take 2–3 months of consistent dosing.

Is this FDA-approved?

Enclomiphene has not received FDA approval as a standalone drug (NDA was submitted but not approved). It is available as a patient-specific 503A compounded preparation from Genesis Compounding under a valid prescriber order.